AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 290: H1798-H1807, 2006. First published December 9, 2005; doi:10.1152/ajpheart.00631.2005
0363-6135/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/5/H1798    most recent
00631.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, Y.
Right arrow Articles by Schwartz, G. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, Y.
Right arrow Articles by Schwartz, G. G.

The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs

Ya Xu, Li Lu, Clifford Greyson, Mona Rizeq, Karin Nunley, Beata Wyatt, Michael R. Bristow, Carlin S. Long, and Gregory G. Schwartz

Cardiology Section, Veterans Affairs Medical Center and University of Colorado Health Sciences Center, Denver, Colorado

Submitted 13 June 2005 ; accepted in final form 22 November 2005


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Rodent studies suggest that peroxisome proliferator-activated receptor-{alpha} (PPAR-{alpha}) activation reduces myocardial ischemia-reperfusion (I/R) injury and infarct size; however, effects of PPAR-{alpha} activation in large animal models of myocardial I/R are unknown. We determined whether chronic treatment with the PPAR-{alpha} activator fenofibrate affects myocardial I/R injury in pigs. Domestic farm pigs were assigned to treatment with fenofibrate 50 mg·kg–1·day–1 orally or no drug treatment, and either a low-fat (4% by weight) or a high-fat (20% by weight) diet. After 4 wk, 66 pigs underwent 90 min low-flow regional myocardial ischemia and 120 min reperfusion under anesthetized open-chest conditions, resulting in myocardial stunning. The high-fat group received an infusion of triglyceride emulsion and heparin during this terminal experiment to maintain elevated arterial free fatty acid (FFA) levels. An additional 21 pigs underwent 60 min no-flow ischemia and 180 min reperfusion, resulting in myocardial infarction. Plasma concentration of fenofibric acid was similar to the EC50 for activation of PPAR-{alpha} in vitro and to maximal concentrations achieved in clinical use. Myocardial expression of PPAR-{alpha} mRNA was prominent but unaffected by fenofibrate treatment. Fenofibrate increased expression of carnitine palmitoyltransferase (CPT)-I mRNA in liver and decreased arterial FFA and lactate concentrations (each P < 0.01). However, fenofibrate did not affect myocardial CPT-I expression, substrate uptake, lipid accumulation, or contractile function during low-flow I/R in either the low- or high-fat group, nor did it affect myocardial infarct size. Despite expression of PPAR-{alpha} in porcine myocardium and effects of fenofibrate on systemic metabolism, treatment with this PPAR-{alpha} activator does not alter myocardial metabolic or contractile responses to I/R in pigs.

nuclear receptor; fibric acid derivative; energy metabolism; cytokine; ventricular function

PEROXISOME proliferator-activated receptors (PPARs) are nuclear receptors involved in regulation of energy substrate metabolism and inflammatory responses. Millions of patients are treated with fibrate PPAR-{alpha} activators for dyslipidemia, and many of these patients have, or are at risk to develop, ischemic heart disease. Although there is prominent expression of PPAR-{alpha} in myocardium (12), the function of PPAR-{alpha} in the heart remains uncertain. In particular, it is unknown whether activation of PPAR-{alpha} modifies responses to myocardial ischemia-reperfusion (I/R) injury.

Several studies in rodents have indicated that pharmacological activation of PPAR-{alpha} is protective in myocardial I/R, helping to preserve contractile function and/or reduce infarct size (6, 29, 32, 37). On the other hand, transgenic mice with cardiac-specific overexpression of PPAR-{alpha} develop a cardiomyopathy characterized by excessive myocardial neutral lipid accumulation (11, 13), and PPAR-{alpha} null mice have better functional recovery from I/R than wild-type mice, particularly when circulating free fatty acids (FFA) are elevated. (21). Finally, while compensated left ventricular (LV) hypertrophy in the mouse is associated with deactivation of PPAR-{alpha} and a switch from FFA to glucose metabolism (5), reactivation of PPAR-{alpha} with a ligand restores myocardial FFA utilization and produces severe contractile dysfunction (36). In sum, rodent studies are divided in suggesting a potential for benefit or harm from PPAR-{alpha} activation in myocardial I/R. In large animals, cardiac effects of PPAR-{alpha} activation are undefined. Moreover, there is precedent for significant species variation in PPAR-mediated responses (2, 3, 15, 19). Thus the goal of the present study was to determine the effects of PPAR-{alpha} activation in myocardial I/R injury in pigs, evaluating myocardial substrate utilization, expression of inflammatory mediators, accumulation of neutral lipid, and, most importantly, contractile function.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Treatment groups. The experimental protocol was approved by the Institutional Animal Care and Use Committee. Eighty-seven domestic farm pigs of either sex were obtained at an average weight of 20 kg. Pigs were fed one of two diets, and in each diet group, pigs were either treated with fenofibrate or not. Sixty pigs were fed low-fat (4% by weight) laboratory pig chow (no. 5084, Purina Mills, St. Louis, MO). Of pigs fed this low-fat diet, 33 were treated with fenofibrate (Sigma, St. Louis, MO), 50 mg·kg–1·day–1 orally, and 27 received no treatment. Fenofibrate was mixed into the filling of fruit cookies that were fed by hand to the pigs to ensure ingestion of each dose. Untreated pigs received cookies without added fenofibrate. Twenty-seven pigs were fed a high-fat (20% by weight) diet formulated by Research Diets (New Brunswick, NJ) from Purina no. 5084 chow with added soybean and safflower oils (9.2% each by weight). Because the high-fat diet contains very little saturated fat and no added cholesterol, it is not atherogenic. Casein and soy protein (5.5% each by weight) were added to the high-fat chow to achieve protein content similar to the low-fat chow. Of the pigs fed the high-fat diet, 14 were treated with fenofibrate, 50 mg·kg–1·day–1, and 13 were untreated. During the fourth week of treatment with fenofibrate, venous blood specimens were withdrawn from the thoracic inlet before and ~5 h after dosing to determine plasma concentrations of fenofibric acid, the principal active metabolite of fenofibrate. The 5-h time point was chosen because peak plasma concentrations of fenofibric acid are attained ~5 h after an oral dose of fenofibrate in humans (4).

Anesthesia, surgery, and instrumentation of the heart for low-flow ischemia and reperfusion. After 4 wk of assigned diet with or without fenofibrate treatment, 66 pigs underwent a terminal experiment of low-flow myocardial ischemia and reperfusion. The methods for anesthesia, surgery, instrumentation of the heart, and physiological monitoring have been described previously (35). On the morning of the experiment, after an overnight fast, pigs were given a final dose of fenofibrate mixed in cookie filling or cookies without fenofibrate. Pigs were sedated with ketamine HCl (25 mg/kg im), anesthetized with {alpha}-chloralose (100 mg/kg iv induction, 20–30 mg·kg–1·h–1 iv maintenance), mechanically ventilated with oxygen-enriched air, and wrapped in a circulating warm water blanket to help maintain body temperature (25). Arterial blood glucose was monitored every 15 min, and an intravenous infusion of 10% glucose was adjusted to maintain arterial blood glucose at ~4 mmol/l. Propranolol (1 mg/kg iv) and atropine (0.2 mg/kg iv) were administered to block autonomic reflexes that would otherwise influence measures of intrinsic myocardial function. Normal saline solution was administered at a rate of 150 ml/h iv.

Micromanometer catheters were placed in the aortic arch and LV (Fig. 1). A fluid-filled catheter was placed in the left atrium for injection of microspheres. Bipolar pacing electrodes were affixed to the left atrial appendage and used to maintain heart rate slightly greater than the spontaneous rate. An adjustable hydraulic occluder (In Vivo Metrics, Healdsburg, CA) and an ultrasonic flow probe (Transonic, Ithaca, NY) were placed around the proximal portion of the left anterior descending coronary artery (LAD) to produce and monitor the severity of regional myocardial ischemia. A catheter was placed in the anterior interventricular coronary vein to sample effluent blood from the ischemic region. An array of four ultrasonic crystals was implanted in the subendocardium of the anterior LV in the center of the ischemic region. The crystals were connected to a digital sonomicrometer (Sonometrics, London, Ontario, Canada) to measure the instantaneous regional wall area subtended by each array. In pigs that had been fed the high-fat diet, levels of FFA were elevated during the terminal experiment by infusion of triglyceride emulsion (Liposyn 10%, 50 ml/min) and heparin (15,000 IU iv initially, then 5,000 IU iv hourly).


Figure 1
View larger version (31K):
[in this window]
[in a new window]
  		Fig. 1. Instrumentation of the heart. LV, left ventricle; LA, left atrium.

 
Low-flow I/R protocol. After instrumentation of the heart, steady-state (baseline) measurements of hemodynamics, regional LV function, myocardial blood flow, arterial and coronary venous concentrations of glucose, lactate, and FFA, triglycerides, and plasma concentrations of insulin and fenofibric acid were made. Next, regional low-flow myocardial ischemia was produced by gradual constriction of the LAD using a microsyringe connected to the hydraulic occluder, while coronary flow was continuously monitored with the flowmeter. LAD flow was reduced to 50% of baseline and maintained at this level (±1 ml/min) for 90 min by fine adjustment of the microsyringe. We and others have previously shown that this duration and severity of ischemia in pigs results in profound myocardial stunning but not infarction (17, 24). Fine adjustments of the microsyringe maintained constant LAD flow (precision 1 ml/min) throughout the ischemic period. Lidocaine (0.6 mg/kg iv) was administered before the onset of ischemia and again every 30 min during ischemia to prevent arrhythmias. At 90 min ischemia, a second set of measurements of hemodynamics, LV function, blood flow, and substrate concentrations was made. The LAD occluder was then gradually released over 2–3 min to allow reperfusion. A third set of all measurements was made at 90 min of reperfusion, and a final set of measurements of hemodynamics and LV function was made at 120 min of reperfusion. Selected 10-s intervals of hemodynamic and sonomicrometry data were digitized at a frequency of 200 Hz and analyzed using custom software. After conclusion of the in vivo protocol and euthanasia, the heart was removed and myocardial samples were quickly excised from ischemic and nonischemic regions of the LV for analysis of regional myocardial blood flow, expression of PPAR-{alpha} and carnitine palmitoyltransferase (CPT)-I mRNA, content of proinflammatory cytokines, and presence of intramyocardial lipid by Oil Red O staining. A sample of liver was excised for measurement of CPT-I expression.

Assessment of LV systolic function. Hemodynamic data were digitized at 200 Hz and analyzed using custom software built on a LabView (National Instruments) platform. LV pressure vs. regional wall area loops were recorded during brief suspension of mechanical ventilation. Regional LV contractile function was assessed by fractional systolic wall area reduction and by a regional external work index. The former is a two-dimensional analog to segment shortening in one dimension or ejection fraction in three dimensions. It was calculated as the difference between end-diastolic and end-systolic wall area, divided by end-diastolic wall area. An index of regional external work was calculated as the area of a LV pressure vs. wall area loop inscribed in one cardiac cycle. It should be noted that these measures of contractile function are sensitive to loading conditions, which change during ischemia and reperfusion. However, these measures may be compared between groups under a given experimental condition, provided that loading conditions are similar in both groups.

Measurement of regional myocardial blood flow, substrate uptake, and fenofibric acid concentration. Under each experimental condition, regional myocardial blood flow was measured in three transmural layers with fluorescent microspheres, as previously described (26). Paired blood samples were withdrawn simultaneously from arterial and anterior interventricular coronary vein catheters for measurement of substrate concentrations. Glucose and lactate concentrations were measured using an autoanalyzer (YSI, Yellow Springs, OH). FFA concentration was measured by spectrophotometric assay (Wako Diagnostics) and triglycerides by enzymatic colorimetric assay. Regional myocardial substrate uptake was calculated as the product of transmurally averaged myocardial blood flow and the coronary arteriovenous concentration difference of the substrate of interest. Plasma insulin was measured by radioimmunoassay. Plasma concentration of fenofibric acid was measured by high-performance liquid chromatography and tandem mass spectroscopy, with a lower limit of quantitation of 0.05 µg/ml and precision (coefficient of variation) of 4% (SFBC Analytical Laboratories, North Wales, PA).

Myocardial expression of PPAR-{alpha}. Myocardial homogenates were prepared from frozen specimens of subendocardium from the nonischemic and ischemic regions of five hearts from each of the four diet and treatment groups. Tissue samples were obtained immediately after euthanasia. For each diet group and for each myocardial region (nonischemic or I/R), samples from untreated and fenofibrate-treated pigs were compared on the same gel. Expression of PPAR-{alpha} mRNA was assessed by ribonuclease protection assay by using a riboprobe derived from the published nucleotide sequence for mouse PPAR-{alpha} (GenBank BC016892). RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). Total RNA (10 µg) prepared from each homogenate was hybridized overnight with the PPAR-{alpha} riboprobe at 42°C. Digestion was carried out by using 1:50 ribonuclease T1 (Ambion, Austin, TX), and the protected fragments were separated on a 5% denaturing polyacrylamide gel. The band corresponding to PPAR-{alpha} was quantified with a phosphorimager and ImageQuant software (Amersham, Piscataway, NJ) and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an internal control for RNA loading.

Expression of CPT-I. Probes specific for both the porcine liver (CPT-I{alpha}) and muscle (CPT-Ibeta) genes were amplified from normal pig heart and liver with PCR-ready cDNAs (BioChain, Hayward, CA) by using 20-mer primers complementary to bases 196–215 (forward) and 390–409 (reverse) for CPT-I{alpha} and bases 26–45 (forward) and 182–201(reverse) for CPT-Ibeta, including BamH1 and HindIII cloning sequences. The CPT-I{alpha} and CPT-Ibeta sequences are GenBank AF284831 and AF284832. PCR reactions were carried out using cloned Pfu polymerase (Stratagene, La Jolla, CA), and products were gel-purified using QIAquick gel extraction (QIAGEN, Valencia, CA). After sequential digestions with BamH1 and HindIII, probe sequences were cloned into pBSII(SK–) (Stratagene) by using T4 DNA Ligase (Invitrogen). Antisense transcripts to both CPT-I genes and human 18S were prepared with MEGAshortscript (Ambion) with removal of unincorporated nucleotides by MEGAclear. Probes were subsequently mixed and hybridized overnight with 15 µg of RNA from myocardium (subendocardium from I/R region) and 15 µg of RNA from liver of each experimental pig. After hybridization, samples were digested with 1:50 A:T1 ribonuclease mix, and protected fragments were separated on a 5% denaturing polyacrylamide gel. Band intensity corrected for RNA loading was expressed as the fraction of the 18S signal.

Proinflammatory cytokines. Myocardial tissue content of three proinflammatory cytokines was measured in subendocardial samples from ischemic-reperfused and nonischemic regions by using enzyme-linked immunosorbent assay kits containing antibodies to porcine interleukin (IL)-1beta and interferon (IFN)-{gamma} (BioSource, Camarillo, CA) and IL-6 (R&D Systems, Minneapolis, MN). We previously demonstrated that cytokine content in nonischemic regions of hearts subjected to regional ischemia and reperfusion was similar to that measured in sham experiments with identical anesthesia, instrumentation, and time course, but without I/R (35).

Assessment of myocardial lipid content by Oil Red O staining. Frozen subendocardial samples from nonischemic and I/R regions of each heart were sectioned with a cryostat (12–15 µm thickness) and stained with Oil Red O for examination under 100x to 600x magnification. Each sample was given a semiquantitative score based on the following criteria: 0, no visible Oil Red O staining; 1, light patchy staining involving a minority of cells in each field; 2, moderate staining involving up to half the cells in each field; 3, intense staining involving the majority of cells in each field. The scores of three blinded observers (M. Rizeq, G. G. Schwartz, and Y. Xu) were averaged.

Effect of fenofibrate on myocardial infarct size. Twenty-one additional pigs from the low-fat diet group were treated with fenofibrate, 50 mg·kg–1·day–1 orally, for 4 wk with the last dose on the morning of the terminal experiment (n = 10), or received no treatment (n = 11). These pigs underwent a terminal experiment of 60-min complete occlusion of the LAD, followed by 180 min reperfusion. Amiodarone (30 mg/kg iv loading dose followed by 0.5 mg·kg–1·min–1 iv infusion) was administered beginning 45 min before ischemia, and lidocaine, 1 mg/kg iv, was administered before ischemia and every 30 min during ischemia and reperfusion. Ventricular fibrillation was treated by defibrillation with internal paddles. After euthanasia, myocardial infarct size was quantified as described by Downey et al. (10). The LAD was reoccluded, the ascending aorta cross-clamped, and 20 ml of 2% Evans blue solution was infused into the aortic root. The heart was excised, cooled in iced saline solution, wrapped in plastic food wrap, placed at –80°C for 30 min, and sliced from apex to base into 3-mm-thick rings. Right ventricular tissue was removed and rings were weighed, incubated in 1% triphenyltetrazolium chloride (TTC) solution at 37°C for 20 min followed by 10% formalin for 15 min, and then photographed with a digital camera. Images were analyzed using Image J software (National Institutes of Health, Bethesda, MD). Area at risk was defined by the absence of Evans blue staining and area of infarction by the absence of TTC staining.

Statistical analysis. Data are expressed as means ± SE. Variables with one measurement per pig were analyzed by two-way ANOVA with factors fat availability and treatment assignment. Variables with more than one measurement per pig were analyzed by three-way ANOVA with factors fat availability, treatment assignment, and either experimental condition or myocardial region (repeated measures of the last factor). Main effects of each factor and key interactions between factors were examined in each model. A significance level of 0.05 was specified for all analyses.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Growth and development. Growth and development were similar with low- or high-fat diet and with fenofibrate treatment or no treatment. At the time of the terminal experiment, pigs fed the low-fat diet weighed 30 ± 1 kg (fenofibrate treated) and 29 ± 1 kg (untreated); pigs fed the high-fat diet weighed 31 ± 2 kg (fenofibrate treated) and 31 ± 1 kg (untreated). Whole heart weights in these four groups were 153 ± 6, 160 ± 9, 159 ± 9, and 159 ± 4 g, respectively [P = not significant (NS)].

Arrhythmia. During low-flow I/R, 6 of 23 pigs (26%) in the low-fat/fenofibrate group and 3 of 16 pigs (19%) in the low-fat/untreated group developed ventricular fibrillation; one pig in each group was successfully defibrillated, completed the experimental protocol, and provided analyzable data. A total of 18 pigs in the low-fat/fenofibrate group and 14 pigs in the low-fat/untreated group completed the experimental protocol. In the high-fat/fenofibrate and high-fat/untreated groups, respectively, 3 of 14 pigs (21%) and 1 of 13 pigs (8%) suffered lethal ventricular fibrillation during low-flow I/R. A total of 11 pigs in the high-fat/fenofibrate group and 12 pigs in the high-fat/untreated group completed the low-flow I/R protocol. Of 21 pigs subjected to experimental myocardial infarction, all but one suffered at least one episode of ventricular fibrillation. Ten pigs (4 untreated and 6 fenofibrate treated) could not be defibrillated, leaving six untreated and five fenofibrate-treated pigs that completed the protocol and provided analyzable data. There was no significant difference in the incidence of ventricular fibrillation between fenofibrate-treated and untreated pigs in either diet group or in either ischemia protocol.

Expression of PPAR-{alpha}. Myocardial PPAR-{alpha} expression (normalized to GAPDH) was compared in untreated and fenofibrate-treated pigs in both low- and high-fat groups. There was prominent expression of PPAR-{alpha} in both nonischemic and I/R regions of all hearts (Fig. 2). However, PPAR-{alpha} expression was unaffected by fenofibrate treatment in either the low-fat or the high-fat group or in either myocardial region.


Figure 2
View larger version (38K):
[in this window]
[in a new window]
  		Fig. 2. Myocardial expression of peroxisome proliferator-activated receptor (PPAR)-{alpha} mRNA by ribonuclease protection assay. A: representative lanes from ribonuclease protection assays demonstrating myocardial expression of PPAR-{alpha} and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. From left to right, the 4 panels show examples from low-fat availability/non-ischemic region, low-fat availability/ischemic-reperfused (Isc/Rep) region, high-fat availability/nonischemic region, and high-fat availability/ischemic-reperfused region. Each panel shows results from 2 untreated and 2 fenofibrate-treated hearts. B: group data, expressed as means ± SE with 11–18 samples in each category. In each gel, the PPAR-{alpha}/GAPDH ratio in each lane was normalized to the mean ratio of the samples from untreated hearts in that gel. Fenofibrate treatment had no effect on PPAR-{alpha} mRNA expression under conditions of either low or high fat availability or in either myocardial region.

 
Plasma concentration of fenofibric acid. After 3 wk of daily treatment, peak and trough plasma concentrations of fenofibric acid were 15 ± 2 and 3 ± 1 µg/ml (47 ± 6 and 9 ± 1 µM) in the low-fat group, and 25 ± 3 and 5 ± 1 µg/ml (78 ± 9 and 15 ± 3 µM) in the high-fat group. Higher concentrations in the high-fat group are consistent with the enhanced absorption of fenofibrate with a fatty meal. During the terminal experiment of I/R, plasma fenofibric acid concentration averaged 7 ± 1 µg/ml (22 ± 3 µM) in both low-fat and high-fat groups. These concentrations are similar to those achieved in human subjects treated with maximum approved dosages of fenofibrate (4) and to the EC50 of fenofibric acid for activation of murine or human PPAR-{alpha} in vitro (18–30 µM) (34). The demonstration of PPAR-{alpha} expression in myocardium and of pharmacologically relevant concentrations of fenofibric acid in plasma fulfills two necessary conditions for potential cardiac effects of a PPAR-{alpha} activator in this model.

Expression of CPT-I. The mRNA expression of CPT-I{alpha} (liver isoform) and CPT-Ibeta (muscle isoform) are shown in Fig. 3. In liver, expression of CPT-I{alpha} was greater in pigs treated with fenofibrate compared with untreated pigs (P < 0.01). This effect of fenofibrate treatment was more prominent in the low-fat groups than in the high-fat groups (interaction P = 0.08). In myocardium, expression of CPT-Ibeta was not affected by fenofibrate treatment in either low-fat or high-fat groups.


Figure 3
View larger version (12K):
[in this window]
[in a new window]
  		Fig. 3. Liver and myocardial expression of carnitine palmitoyltransferase-I (CPT-I) mRNA. Left: expression of CPT-1{alpha} (liver isoform) in porcine liver. Right: expression of CPT-1beta (muscle isoform) in porcine subendocardial myocardium. Measurements are means ± SE with n = 12 in each category. Two-way ANOVA with factors fat availability and treatment showed that fenofibrate treatment had a significant positive main effect on expression of CPT-1{alpha} in liver (*P < 0.01) but had no significant effect on expression of CPT-Ibeta in myocardium.

 
Circulating substrate concentrations and myocardial substrate utilization. During the fourth week of assigned diet, plasma FFA concentration was measured before and 5 h after a feeding; these two measurements did not differ significantly in any group, and data in Table 1 represent the average of the two measurements in each pig. As expected, FFA levels measured during the fourth week of assigned diet were higher (P < 0.001) in pigs fed the high-fat diet compared with the low-fat diet. FFA levels measured during dietary intervention tended to be lower with fenofibrate treatment; this effect approached but did not reach statistical significance (P = 0.09).


View this table:
[in this window]
[in a new window]
  		Table 1. Plasma FFA concentration during chronic feeding of low-fat or high-fat diet

 
Table 2 shows arterial concentrations of insulin, glucose, lactate, and FFA measured during the terminal experiment under preischemic conditions, at 90 min of low-flow ischemia, and after 90 min of reperfusion. Arterial insulin and glucose concentrations were similar in all groups and under all conditions. As expected, arterial FFA concentrations were higher under high-fat conditions than under low-fat conditions (P < 0.001). Treatment with fenofibrate significantly reduced arterial FFA concentration (P < 0.01) and arterial lactate concentration (P < 0.001) during the terminal I/R experiment. In conjunction with the increased liver expression of CPT-I{alpha}, these findings indicate a significant systemic metabolic effect of fenofibrate in this model. Under low-fat conditions, arterial triglyceride concentrations were below the lower limit of the assay system (0.17 mmol/l) in the majority of pigs. Under high-fat conditions, arterial triglyceride concentration was 0.5 ± 0.1 mmol/l in both the untreated and the fenofibrate-treated group.


View this table:
[in this window]
[in a new window]
  		Table 2. Arterial substrate concentrations during terminal experiment

 
Despite the effect of fenofibrate treatment on arterial FFA and lactate concentrations, there was no accompanying effect of fenofibrate on myocardial substrate uptake: Fig. 4 shows myocardial substrate uptake before, during, and after low-flow ischemia. As expected, high-fat conditions increased myocardial FFA uptake and reciprocally decreased myocardial glucose and lactate uptake compared with low-fat conditions. However, fenofibrate treatment had no effect on myocardial FFA, glucose, or lactate uptake under either high-fat or low-fat conditions. Myocardial triglyceride uptake could not be measured under low-fat conditions because of low circulating concentrations. Under high-fat conditions, myocardial triglyceride uptake averaged 0.03 mmol·g–1·min–1 in both untreated and fenofibrate-treated pigs under preischemic conditions and fell to nil in both groups during ischemia and reperfusion.


Figure 4
View larger version (12K):
[in this window]
[in a new window]
  		Fig. 4. Myocardial substrate uptake. Data are from a terminal low-flow ischemia-reperfusion experiment that followed 4 wk of feeding either a low-fat or a high-fat diet (see text). Uptake of free fatty acids (FFA), glucose, and lactate in the ischemic-reperfused region of the left ventricle are plotted as means ± SE, with 11–19 pigs in each group. Pre-isc, baseline before ischemia; Isc, at 90 min ischemia; Rep, at 90 min of reperfusion. In the groups fed a high-fat diet, arterial FFA concentrations were increased in the terminal experiment by infusion of triglyceride emulsion and heparin. In 3-way ANOVA with factors fat availability, fenofibrate treatment, and experimental condition, high-fat conditions increased myocardial FFA uptake and decreased glucose and lactate uptake (*P < 0.01). However, there was no significant effect of fenofibrate treatment on uptake of any substrate.

 
Hemodynamics, myocardial blood flow, and LV contractile function. Baseline (preischemic) hemodynamics, myocardial blood flow, and measures of regional LV systolic function were similar in each group (Table 3). Compared with pigs in the low-fat group, pigs in the high-fat group had lower mean aortic and LV systolic pressure, particularly during ischemia and reperfusion. Total LAD flow was higher and transmural anterior LV blood flow was lower in the high-fat compared with the low-fat groups; however, blood flow to the subendocardium of the ischemic region (where contractile function and cytokine expression were measured) did not differ in any group. As expected, contractile function declined during ischemia and remained depressed after reperfusion in all groups (Fig. 5). Importantly, fenofibrate treatment had no effect on any of these variables at either fat level or under any experimental condition.


View this table:
[in this window]
[in a new window]
  		Table 3. Hemodynamics and myocardial blood flow

 

Figure 5
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 5. Regional LV systolic function (regional external work). Regional external work of the ischemic-reperfused region of the left ventricle is plotted as a fraction of baseline (preischemic) values. The absolute values of regional external work were similar at baseline in all 4 groups (see Table 2). Data are means ± SE with 11–19 pigs in each group. Pre-isc, preischemic baseline; Isc, at 90 min ischemia; Rep, at 90–120 min reperfusion. In all groups, regional external work declined during ischemia and declined further during reperfusion. However, there were no significant differences in regional external work among groups.

 
Expression of proinflammatory cytokines. Figure 6 shows IL-6, IL-1beta, and IFN-{gamma} protein concentrations in subendocardial samples from nonischemic and I/R regions of the LV. By three-way ANOVA, there was a significant positive main effect of I/R on expression of each cytokine. The effect of I/R was evident under both low- and high-fat conditions for IL-6, but only under low-fat conditions for IL-1beta and IFN-{gamma}. Fenofibrate treatment had a modest but significant negative main effect on expression of IL-1beta (P < 0.05) but no main effect on expression of IL-6 or IFN-{gamma}.


Figure 6
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 6. Proinflammatory myocardial cytokine expression. Protein expression by enzyme-linked immunosorbent assay expressed as ng/g protein content. Top: interleukin (IL)-6. Middle: IL-1beta. Bottom: interferon (IFN)-{gamma}. Data are means ± SE of 10–14 pigs in each group. In 3-way ANOVA models with factors fenofibrate treatment, fat availability, and myocardial region, there was a significant negative main effect of fenofibrate treatment on IL-1beta (*P < 0.05) but not on IL-6 or IFN-{gamma}. non-isc, Nonischemic; rep, reperfused; LF, low fat availability; HF, high fat availability.

 
Intramyocardial neutral lipid. Representative photomicrographs and group semiquantitative scores of Oil Red O staining in subendocardial samples are shown in Fig. 7. By three-way ANOVA, there was a significant positive main effect of high-fat conditions (P < 0.001). There was also a significant interaction (P < 0.05) between myocardial region and fat availability, such that lipid accumulation was increased by I/R under high-fat but not low-fat conditions. However, there was no effect of fenofibrate treatment on myocardial lipid accumulation at either fat level or in either myocardial region.


Figure 7
View larger version (75K):
[in this window]
[in a new window]
  		Fig. 7. Intramyocardial neutral lipid accumulation assessed by Oil Red O staining: Top: representative photomicrographs (600x) showing pattern of Oil Red O staining in previously frozen subendocardial samples from ischemic-reperfused (I/R) region of hearts from pigs administered 4 wk of low-fat or high-fat diet, with or without fenofibrate treatment. Pigs in the high-fat groups received an infusion of triglyceride emulsion and heparin during the terminal I/R experiment to maintain elevated fat availability. In the specimens from the low-fat groups, there is patchy staining with Oil Red O involving a small minority of myocytes. In the specimens from the high-fat groups, there is more pronounced staining involving approximately half of the myocytes. Bottom: semiquantitative histologic score of Oil Red O staining in subendocardial samples. A score of 0 was assigned for no staining, 1 for light patchy staining involving a minority of cells in each field, 2 for moderate staining involving up to half the cells in each field, or 3 for intense staining involving the majority of cells in each field. Data are means ± SE with 11–19 pigs in each group. U, untreated; F, fenofibrate-treated. In 3-way ANOVA with factors fat availability, fenofibrate treatment, and myocardial region, there was a significant positive main effect of high fat (*P < 0.001) but no significant effect of fenofibrate treatment on Oil Red O score.

 
Myocardial infarct size. As shown in Table 4, there was no significant difference between groups in area at risk and no significant effect of fenofibrate treatment on infarct size.


View this table:
[in this window]
[in a new window]
  		Table 4. Myocardial infarct size

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In a model of I/R in the in situ porcine heart, 1 mo of pretreatment with the PPAR-{alpha} activator fenofibrate had no effect on myocardial substrate utilization, lipid accumulation, contractile function, or infarct size. Effects of treatment were absent even under conditions of increased FFA availability. A protective effect of fenofibrate was absent despite fulfillment of three necessary conditions for such an effect: expression of PPAR-{alpha} in porcine myocardium was prominent; concentrations of fenofibric acid in plasma were comparable to the EC50 for activation of PPAR-{alpha} in vitro (34) and to concentrations achieved in effective clinical use of fenofibrate (4); and biological activity of fenofibrate in this model was evident from a significant increase in liver expression of CPT-I{alpha}, a decrease in arterial FFA and lactate concentrations during the terminal I/R experiment, and a decrease in myocardial IL-1beta expression.

We chose to use fenofibrate as the test compound in these experiments because it is used widely in clinical practice, because its active metabolite fenofibrate distributes well to myocardium (33), and because established methods exist to measure fenofibric acid concentration in plasma. Among the fibric acid derivatives in current clinical use, fenofibrate has the highest affinity and is the most selective for PPAR-{alpha}. Synthetic ligands with higher affinity for PPAR-{alpha} than fenofibrate have been developed (34) but are untested in large animals or humans and have no established methods for measurement of plasma concentrations.

The neutral findings of the present study stand in contrast to the protective effects of PPAR-{alpha} activation demonstrated in several prior studies of myocardial I/R in rodents. Wayman et al. (32) showed that acute treatment with clofibrate or WY-14643 (0.3–1.0 mg/kg), administered 30 min before 25-min occlusion of the anterior descending coronary artery and 2 h of reperfusion in rats, reduced infarct size by ~40%. Bulhak et al. (6) reported similar findings using a similar model. Taberno et al. (29) subjected mice to 30 min global no-flow ischemia and 1-h reperfusion. Ten days of pretreatment with fenofibrate (15 mg/day) reduced infarct size to ~5% of LV mass compared with ~20% of LV mass in untreated mice. There was also a beneficial effect of fenofibrate on recovery of contractile function. Moreover, these investigators found no protective effect of fenofibrate in PPAR-{alpha} null mice, indicating that the protective effects in wild-type mice are likely mediated through PPAR-{alpha}. Similarly, Yue et al. (37) found that 2 days of pretreatment with the PPAR-{alpha} activator GW-7647 reduced myocardial infarct size and postischemic contractile dysfunction in wild-type mice. Protection by GW-7647 was associated with inhibition of nuclear factor (NF)-{kappa}B in the heart and decreased expression of proinflammatory cytokines but was not evident in PPAR-{alpha} null mice. Other studies have found protective effects of PPAR-{alpha} activation in splanchnic (8) and renal (27) I/R injury in rats. In the former case, protection was associated with reduced expression of proinflammatory cytokines in the gut. In sum, these studies indicate that pharmacological activation of PPAR-{alpha} significantly attenuates I/R injury in rodents.

On the other side of the coin, studies in transgenic mice with cardiac-specific overexpression of PPAR-{alpha} suggest that excessive signaling through this pathway may be deleterious. These mice not only demonstrate increased myocardial expression of proteins involved in fatty acid uptake and oxidation but also exhibit a pathological phenotype characterized by myocardial lipid accumulation, biventricular hypertrophy, and contractile dysfunction (13). The severity of cardiomyopathy was exacerbated by feeding a high-fat diet (11). In contrast, we found that exposure of pigs to a PPAR-{alpha} activator caused no impairment of cardiac function and no increase in myocardial lipid content, even under conditions of increased FFA availability.

The absence of either protective or deleterious effects of fenofibrate in the present study may reflect species differences in ligand activation and effects of PPAR-{alpha}. The precedent for such differences is well established in tissues other than myocardium and in species other than pig (2, 7). For example, fibrates are more effective than linoleic acid in promoting PPAR-{alpha} activation in cultured rat hepatoma cells, whereas linoleic acid is more effective than fibrates in human hepatoma cells (2). Fenofibrate increases the expression of fatty acyl-CoA oxidase in rat hepatocytes but not human hepatocytes (16). Similarly, perioxisome proliferation in response to activation of PPAR-{alpha} is observed in rat but not human hepatocytes (3, 7). Fibrates decrease hepatic expression of apolipoprotein A-I in rodents but increase expression in humans (30). These differences appear to be independent of the level of PPAR-{alpha} expression (16, 19) and rather may reflect species differences in the ligand-binding domain of the receptor (15). Analogous to the findings in the present study, PPAR-{gamma} activation with thiazolidinedione compounds is not protective in myocardial I/R in pigs (35) but appears to be protective in rodents (32, 38).

The absence of observed effects of fenofibrate on myocardial substrate uptake in the current experiments is consistent with the fact that we did not observe an effect of treatment on myocardial CPT-I expression. Taken in the context of the significant effects of fenofibrate on liver CPT-I expression and plasma FFA and lactate concentrations, our findings indicate significant tissue specificity of response to PPAR-{alpha} activation in the pig. Our findings are consistent with a study showing that mice pretreated with a PPAR-{alpha} agonist for 8 wk did not differ from untreated mice in terms of myocardial glucose or FFA oxidation or myocardial expression of PPAR-{alpha} or PPAR-{alpha} target genes (1). However, our findings contrast with observations in cultured neonatal rat cardiomyocytes, in which exposure to PPAR-{alpha} ligands increases FFA oxidation along with the expression of genes involved in fatty acid transport and oxidation (14).

Anti-inflammatory effects of PPAR-{alpha} are thought to be mediated through negative regulation of the transcription factors NF-{kappa}B and activator protein-1, resulting in decreased expression of their target genes, particularly IL-6 (9, 22, 28). However, we observed no effect of fenofibrate treatment on myocardial IL-6 expression. Fibrates have also been reported to reduce levels of IL-1beta in plasma (31) and to attenuate expression of IFN-{gamma} by T-lymphocytes (18, 20). We did observe a quantitatively modest albeit statistically significant attenuation of myocardial IL-1beta expression with fenofibrate. The physiological importance of this effect is uncertain. We also observed that myocardial IL-1beta and IFN-{gamma} did not increase with I/R under high-fat conditions. This may reflect an anti-inflammatory effect of the n-6 polyunsaturated fatty acids (23), which were a large component of the high-fat diet enriched in soybean and safflower oils.

A limitation of this study is that we tested only one dose of fenofibrate because of the large number of pigs required for the experiments. We cannot exclude the possibility that use of a higher dose of fenofibrate or another PPAR-{alpha} activator would have produced different effects. However, we believed that it was most important to evaluate an agent already in wide clinical use at a dose that results in clinically relevant plasma concentrations of the active metabolite.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by National Heart, Lung, and Blood Institute Grants HL-49944 (G. G. Schwartz) and HL-68606 (C. Greyson) and the Medical Research Service of the Department of Veterans Affairs.


   ACKNOWLEDGMENTS
 
We thank Dr. Allan Edgar, Fournier Pharma, Daix, France, and Dr. Allan Xu, SFBC Anapharm, North Wales, PA, for assistance in measurement of fenofibric acid concentrations.


   FOOTNOTES
 

Address for reprint requests and other correspondence: G. G. Schwartz, Cardiology Section (111B), Denver VA Medical Center (111B), 1055 Clermont St., Denver, CO 80220 (e-mail: Gregory.Schwartz{at}med.va.gov)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Aasum E, Cooper M, Severson DL, and Larson TS. Effect of BM 17.0744, a PPAR-{alpha} ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 83: 183–190, 2005.[CrossRef][Web of Science][Medline]
  2. Akbiyik F, Ray DM, Bozkaya H, and Demirpence E. Ligand- and species-dependent activation of PPAR-{alpha}. Cell Physiol Biochem 14: 269–276, 2004.[CrossRef][Web of Science][Medline]
  3. Ammerschlaeger M, Beigel J, Klein KU, and Mueller SO. Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci 78: 229–240, 2004.[Abstract/Free Full Text]
  4. Balfour JA, McTavish D, and Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40: 260–290, 1990.[Web of Science][Medline]
  5. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, and Kelly DP. Deactivation of peroxisome proliferator-activated receptor-{alpha} during cardiac hypertrophic growth. J Clin Invest 105: 1723–1730, 2000.[Web of Science][Medline]
  6. Bulhak A, Sjoquist PO, and Pernow J. Activation of PPAR-{alpha} protects the myocardium from ischaemia-reperfusion injury: Involvement of nitric oxide. Cardiovasc J S Afr 15: S11–S12, 2004.
  7. Choudhury AI, Chahal S, Bell AR, Tomlinson SR, Roberts RA, Salter AM, and Bell DR. Species differences in peroxisome proliferation; mechanisms and relevance. Mutat Res 448: 201–212, 2000.[Web of Science][Medline]
  8. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, and Caputi AP. WY 14643, a potent exogenous PPAR-{alpha} ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock 22: 340–346, 2004.[CrossRef][Web of Science][Medline]
  9. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, and Staels B. Peroxisome proliferator-activated receptor {alpha} negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-{kappa}B and AP-1. J Biol Chem 274: 32048–32054, 1999.[Abstract/Free Full Text]
  10. Downey JM. Measuring infarct size by the tetrazolium method [Online]. In: The International Society for Heart Research Handbook of Experimental Laboratory Procedures, edited by Downey JM. International Society for Heart Research, 2005. [http://www.southalabama.edu/ishr/help/ttc].
  11. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP. A critical role for PPAR{alpha}-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100: 1226–1231, 2003.[Abstract/Free Full Text]
  12. Finck BN and Kelly DP. Peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 34: 1249–1257, 2002.[Web of Science][Medline]
  13. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, and Kelly DP. The cardiac phenotype induced by PPAR{alpha} overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121–130, 2002.[CrossRef][Web of Science][Medline]
  14. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) {alpha} and PPARbeta/{delta}, but not PPAR{gamma}, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518–524, 2003.[Abstract/Free Full Text]
  15. Keller H, Devchand PR, Perroud M, and Wahli W. PPAR-{alpha} structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem 378: 651–655, 1997.[Web of Science][Medline]
  16. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, and Zhou G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) {alpha}. PPAR-{alpha} fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 276: 31521–31527, 2001.[Abstract/Free Full Text]
  17. Lu L, Xu Y, Greyson C, Ursell PC, and Schwartz GG. Nonelastic deformation of myocardium in low-flow ischemia and reperfusion: ultrastructure-function relations. J Mol Cell Cardiol 31: 1157–1169, 1999.[CrossRef][Web of Science][Medline]
  18. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, and Plutzky J. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90: 703–710, 2002.[Abstract/Free Full Text]
  19. Mukherjee R, Jow L, Noonan D, and McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 51: 157–166, 1994.[CrossRef][Web of Science][Medline]
  20. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Labuzek K, and Herman ZS. The effect of statins and fibrates on interferon-{gamma} and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176: 327–335, 2004.[CrossRef][Web of Science][Medline]
  21. Panagia M, Gibbons GF, Radda GK, and Clarke K. PPAR-{alpha} activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 288: H2677–H2683, 2005.[Abstract/Free Full Text]
  22. Reiterer G, Toborek M, and Hennig B. Peroxisome proliferator-activated receptors {alpha} and {gamma} require zinc for their anti-inflammatory properties in porcine vascular endothelial cells. J Nutr 134: 1711–1715, 2004.[Abstract/Free Full Text]
  23. Sadeghi S, Wallace FA, and Calder PC. Dietary lipids modify the cytokine response to bacterial lipopolysaccharide in mice. Immunology 96: 404–410, 1999.[CrossRef][Web of Science][Medline]
  24. Schulz R, Guth BD, Pieper K, Martin C, and Heusch G. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. Circ Res 70: 1282–1295, 1992.[Abstract/Free Full Text]
  25. Schwartz GG, Schaefer S, Trocha SD, Garcia J, Steinman S, Massie BM, and Weiner MW. Effect of supranormal coronary blood flow on energy metabolism and systolic function of porcine left ventricle. Cardiovasc Res 26:1001–1006, 1992.[Abstract/Free Full Text]
  26. Schwartz GG, Xu Y, Greyson CR, Cohen J, and Lu L. Low-dose inotropic stimulation during left ventricular ischaemia does not worsen post-ischaemic dysfunction. Cardiovasc Res 32: 1024–1037, 1996.[Abstract/Free Full Text]
  27. Sivarajah A, Chatterjee PK, Hatori Y, Brown PA, Stewart KN, Todorovic Z, Mota-Filipe H, and Thiemermann C. Agonists of the peroxisome proliferator-activated receptor-{alpha} (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit 8: BR532–BR539, 2002.[Medline]
  28. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPAR{alpha} but not by PPAR{gamma} activators. Nature 393: 790–793, 1998.[CrossRef][Medline]
  29. Taberno A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, and Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor {alpha} protects against myocardial ischaemic injury and improves endothelial vasodilation. BMC Pharmacol 2: 10, 2002.[CrossRef][Medline]
  30. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, and Staels B. The nuclear receptors peroxisome proliferator-activated receptor {alpha} and Rev-erb{alpha} mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273: 25713–25720, 1998.[Abstract/Free Full Text]
  31. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, and Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170: 315–323, 2003.[CrossRef][Web of Science][Medline]
  32. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, and Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-{gamma} and PPAR-{alpha}) reduce myocardial infarct size. FASEB J 16: 1027–1040, 2002.[Abstract/Free Full Text]
  33. Weil A, Caldwell J, and Strolin-Benedetti M. The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab Dispos 16: 302–309, 1988.[Abstract]
  34. Willson TM, Brown PJ, Sternbach DD, and Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 43: 527–550, 2000.[CrossRef][Web of Science][Medline]
  35. Xu Y, Gen M, Lu L, Fox J, Weiss SO, Brown RD, Perlov D, Ahmad H, Zhu P, Greyson C, Long CS, and Schwartz GG. PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 288: H1314–H1323, 2005.[Abstract/Free Full Text]
  36. Young ME, Laws FA, Goodwin GW, and Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor {alpha} is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276: 44390–44395, 2001.[Abstract/Free Full Text]
  37. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindham K, and Ohlstein EH. Activation of the peroxisome proliferator-activated receptor-{alpha} protects the heart from ischemia/reperfusion injury. Circulation 108: 2393–2399, 2003.[Abstract/Free Full Text]
  38. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, and Ohlstein EH. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone. Circulation 104: 2588–2594, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 HypertensionHome page
T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam
Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload
Hypertension, May 1, 2007; 49(5): 1084 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Shiroshita-Takeshita, B. J.J.M. Brundel, B. Burstein, T.-K. Leung, H. Mitamura, S. Ogawa, and S. Nattel
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure
Cardiovasc Res, April 1, 2007; 74(1): 75 - 84.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/5/H1798    most recent
00631.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, Y.
Right arrow Articles by Schwartz, G. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, Y.
Right arrow Articles by Schwartz, G. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.